Sparrow BioAcoustics has raised $10 million in new financing to accelerate the expansion of its AI-driven cardiac assessment platform across hospitals in North America. The funding round was led by Killick Capital and Klister Credit, with participation from Pelorus VC, 98827 Newfoundland & Labrador Inc., and Brinex Capital.
The Canadian health technology company plans to use the new capital to scale its operations responsibly while supporting growing adoption of its FDA-cleared Stethophone platform, which enables bioacoustic detection of heart anomalies directly through a smartphone. The Stethophone system utilizes artificial intelligence to detect structural and rhythmic irregularities, allowing clinicians to perform advanced cardiac screenings without requiring additional hardware.
Sparrow’s growth comes as hospitals increasingly seek practical, scalable solutions to detect heart conditions earlier and more accurately. The company’s AI Phonoscopy technology transforms ordinary smartphones into medical-grade diagnostic tools, bridging accessibility gaps in cardiac care.
A peer-reviewed study published in the International Journal of Medical Science and Innovation Research evaluated the Stethophone’s use and accuracy at the University of Washington Medical Center. The study found the AI highly accurate in detecting valvular disease and atrial fibrillation, noting its potential to revolutionize cardiac screening by improving early identification and broadening access to quality cardiovascular assessments.
Sparrow reports that approximately 40,000 patients and practitioners have already used the Stethophone platform, uncovering thousands of cardiac anomalies that might have otherwise remained undiagnosed until later stages. The company continues to expand clinical evaluations at significant sites in the United States and Canada.
In addition to publishing research results, Sparrow presented its latest developments at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco earlier this month and plans to showcase new findings at the American Heart Association Scientific Sessions in New Orleans in November.
KEY QUOTES:
“This round ensures we can scale responsibly through this critical phase, supporting hospitals and patients with the same focus on quality and outcomes that brought us here. It’s about maintaining the momentum we’ve built while continuing to deliver real clinical value where it’s needed most.”
Mark Opauszky, CEO of Sparrow BioAcoustics
“In the past year, about 40,000 patients and practitioners have used Stethophone, uncovering thousands of cardiac anomalies that might otherwise have gone unnoticed until later stages of disease. The demand for practical, scalable screening for conditions such as aortic stenosis continues to grow rapidly, and the feedback from clinicians and patients has been overwhelmingly positive.”
Dr. Yaroslav Shpak, Chief Medical Officer and Co-Founder of Sparrow BioAcoustics
